By Barbara Obstoj-Cardwell. Editor
Among important clinical trial news last week, US pharma giant Merck & Co released positive new data on its PD-1 therapy Keytruda (pembrolizumab) in the treatment of bladder cancer. Also, Vertex Pharmaceuticals reported encouraging new data on its non-opioid acute pain candidate VX-548. On the deal-making front, Austria’s Hookipa Pharma announced that Swiss giant Roche is terminating its collaboration on the HB-700 program in KRAS mutated cancer, as a result of which Hookipa is reprioritizing its focus. Among the fourth-quarter and full-year 2023 financial results that were released last week, Merck & Co’s pruning of its R&D pipeline attracted comment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze